Monitor for any partnership or distribution agreements in Asia that would signal commercialization progress; the patent alone does not generate revenue.
Price Chart
Executive Summary
bioAffinity Technologies announced the Hong Kong Intellectual Property Department granted a patent (HK40048460) for its CyPath Lung noninvasive lung cancer diagnostic technology, complementing a 2025 China patent and strengthening its IP position in Asia, where ~1.6 million new lung cancer cases are diagnosed annually. This is a positive IP milestone but does not change the company's near-term revenue or commercialization timeline.
Key Facts
- Hong Kong patent HK40048460 granted for CyPath Lung's core technology covering flow cytometry and fluorescent markers in sputum
- Complements a 2025 China patent and expands global patent estate including US, Australia, Canada, EU, Japan, Mexico, Singapore
- Asia accounts for an estimated 1.6 million new lung cancer cases annually per IARC GLOBOCAN 2022
- CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary
Financial Impact
No financial figures provided; patent strengthens IP moat for potential Asian market entry but near-term revenue impact is speculative
Risk Factors
- Enforceability of patents in foreign jurisdictions, including Hong Kong and China, is uncertain
- CyPath Lung is an LDT and may require additional regulatory approvals for international markets
- Company remains pre-revenue or early-stage commercial; needs additional capital to fund operations and market expansion
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-043052 |
| Exhibit: ex99-1.htm | 0001493152-26-043052 |
| Document: 0001493152-26-043052-index-headers.html | 0001493152-26-043052 |
| Document: 0001493152-26-043052-index.html | 0001493152-26-043052 |
| Document: 0001493152-26-043052.txt | 0001493152-26-043052 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | DEF 14A | $2.81 | awaiting T+1 | — | $2.95 (+4.99%) |
Oct 15, 2026 12d ago | 8-K | $3.96 $3.73 | ▼ −5.81% | ▼ −4.70% | $2.95 (−25.50%) |
Oct 13, 2026 14d ago | 8-K | $3.63 $3.56 | ▼ −1.79% | ▼ −0.71% | $2.95 (−18.62%) |
Oct 9, 2026 17d ago | 8-K | $3.90 $3.63 | ▲ +7.05% | ▲ +7.04% | $2.95 (+24.36%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 $3.90 | ▲ +17.46% | ▲ +17.40% | $2.95 (+37.56%) |
Oct 9, 2026 18d ago | 424B5 | $4.73 $3.90 | ▼ −17.46% | ▼ −17.40% | $2.95 (−37.56%) |
Oct 8, 2026 19d ago | 8-K | $5.64 $4.73 | ▼ −16.22% | ▼ −16.82% | $2.95 (−47.69%) |
Oct 6, 2026 21d ago | 8-K | $6.06 $6.16 | ▲ +1.65% | ▲ +1.89% | $2.95 (−51.32%) |
Sep 30, 2026 27d ago | 8-K | $6.56 $6.15 | ▼ −6.33% | ▼ −6.50% | $2.95 (−55.03%) |
Sep 22, 2026 5w ago | 8-K | $8.56 $7.94 | ▼ −7.19% | ▼ −6.47% | $2.95 (−65.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers